Published in Mol Cancer on August 27, 2010
Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev (2012) 1.96
MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis (2012) 1.55
ER stress negatively modulates the expression of the miR-199a/214 cluster to regulates tumor survival and progression in human hepatocellular cancer. PLoS One (2012) 1.50
miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer. Oncogene (2012) 1.34
Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis and poor prognosis in small cell carcinoma of the cervix. PLoS One (2012) 1.31
Discoidin domain receptor functions in physiological and pathological conditions. Int Rev Cell Mol Biol (2014) 1.29
Functional screening for miRNAs targeting Smad4 identified miR-199a as a negative regulator of TGF-β signalling pathway. Nucleic Acids Res (2012) 1.24
Identification of deregulated miRNAs and their targets in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol (2012) 1.22
MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ (2014) 1.17
MicroRNAs in hepatocellular carcinoma: regulation, function, and clinical implications. ScientificWorldJournal (2013) 1.16
Up-regulated miR-199a-5p in gastric cancer functions as an oncogene and targets klotho. BMC Cancer (2014) 1.13
MiR-199a attenuates endometrial stromal cell invasiveness through suppression of the IKKβ/NF-κB pathway and reduced interleukin-8 expression. Mol Hum Reprod (2011) 1.10
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. Oncotarget (2014) 1.07
Role of microRNAs in hepatocellular carcinoma: a clinical perspective. Onco Targets Ther (2013) 1.02
Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives. World J Gastroenterol (2014) 1.00
The microRNA miR-199a-5p down-regulation switches on wound angiogenesis by derepressing the v-ets erythroblastosis virus E26 oncogene homolog 1-matrix metalloproteinase-1 pathway. J Biol Chem (2012) 0.97
microRNA-199a-5p protects hepatocytes from bile acid-induced sustained endoplasmic reticulum stress. Cell Death Dis (2013) 0.97
MicroRNA Expression Profiling in Clear Cell Renal Cell Carcinoma: Identification and Functional Validation of Key miRNAs. PLoS One (2015) 0.97
Epigenetics of hepatocellular carcinoma: role of microRNA. World J Gastroenterol (2013) 0.95
MicroRNA-1246 enhances migration and invasion through CADM1 in hepatocellular carcinoma. BMC Cancer (2014) 0.94
Flexible and versatile as a chameleon-sophisticated functions of microRNA-199a. Int J Mol Sci (2012) 0.93
Cholinesterase-Targeting microRNAs Identified in silico Affect Specific Biological Processes. Front Mol Neurosci (2011) 0.90
MicroRNAs dysregulation in hepatocellular carcinoma: Insights in genomic medicine. World J Hepatol (2015) 0.89
miR-199a-5p regulates the expression of metastasis-associated genes in B16F10 melanoma cells. Int J Clin Exp Pathol (2014) 0.86
Identification of differentially expressed microRNAs in human hepatocellular adenoma associated with type I glycogen storage disease: a potential utility as biomarkers. J Gastroenterol (2013) 0.86
MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.85
Clinical implications of microRNAs in liver cancer stem cells. Chin J Cancer (2013) 0.83
MicroRNA MiR-199a-5p regulates smooth muscle cell proliferation and morphology by targeting WNT2 signaling pathway. J Biol Chem (2015) 0.82
High expression of DDR1 is associated with the poor prognosis in Chinese patients with pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res (2015) 0.82
Increase of miR-199a-5p by protoporphyrin IX, a photocatalyzer, directly inhibits E2F3, sensitizing mesenchymal tumor cells to anti-cancer agents. Oncotarget (2015) 0.81
IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway. Oncotarget (2016) 0.81
FZD6 expression is negatively regulated by miR-199a-5p in human colorectal cancer. BMB Rep (2015) 0.79
The miR-199-dynamin regulatory axis controls receptor-mediated endocytosis. J Cell Sci (2015) 0.79
microRNA changes in liver tissue associated with fibrosis progression in patients with hepatitis C. Liver Int (2015) 0.78
miR-214/199a/199a* cluster levels predict poor survival in hepatocellular carcinoma through interference with cell-cycle regulators. Oncotarget (2016) 0.77
MiR-199a inhibits the angiogenic potential of endometrial stromal cells under hypoxia by targeting HIF-1α/VEGF pathway. Int J Clin Exp Pathol (2015) 0.77
Non-coding RNAs in Uterine Development, Function and Disease. Adv Exp Med Biol (2016) 0.77
Inhibition of MiR-199a-5p reduced cell proliferation in autosomal dominant polycystic kidney disease through targeting CDKN1C. Med Sci Monit (2015) 0.76
miR-199a-5p induces cell invasion by suppressing E-cadherin expression in cutaneous squamous cell carcinoma. Oncol Lett (2016) 0.75
Association between miR-199a rs74723057 and MET rs1621 polymorphisms and the risk of hepatocellular carcinoma. Oncotarget (2016) 0.75
MicroRNA-199a-5p promotes tumour growth by dual-targeting PIAS3 and p27 in human osteosarcoma. Sci Rep (2017) 0.75
Mouse-specific up-regulation of Ccnb1 expression by miR-199a-5p in keratinocyte. FEBS Open Bio (2016) 0.75
Survivin downregulation using siRNA nanoliposomes inhibits cell proliferation and promotes the apoptosis of MHCC-97H hepatic cancer cells: An in vitro and in vivo study. Oncol Lett (2017) 0.75
New Insights into the Epigenetics of Hepatocellular Carcinoma. Biomed Res Int (2017) 0.75
Original Research: Analysis of hepatic microRNA alterations in response to hepatitis B virus infection and pegylated interferon alpha-2a treatment. Exp Biol Med (Maywood) (2016) 0.75
Antitumor activity of 7RH, a discoidin domain receptor 1 inhibitor, alone or in combination with dasatinib exhibits antitumor effects in nasopharyngeal carcinoma cells. Oncol Lett (2016) 0.75
MiR-199a-5p and let-7c cooperatively inhibit migration and invasion by targeting MAP4K3 in hepatocellular carcinoma. Oncotarget (2017) 0.75
Suppressing miR-199a-3p by promoter methylation contributes to tumor aggressiveness and cisplatin resistance of ovarian cancer through promoting DDR1 expression. J Ovarian Res (2017) 0.75
Mutual Regulation of MiR-199a-5p and HIF-1α Modulates the Warburg Effect in Hepatocellular Carcinoma. J Cancer (2017) 0.75
Downregulation of discoidin domain receptor 2 decreases tumor growth of hepatocellular carcinoma. J Cancer Res Clin Oncol (2015) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol (2002) 82.19
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 48.95
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell (1993) 33.79
Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res (2005) 29.17
MicroRNA-directed cleavage of HOXB8 mRNA. Science (2004) 18.33
Vertebrate microRNA genes. Science (2003) 17.42
Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet (2002) 17.20
Switching from repression to activation: microRNAs can up-regulate translation. Science (2007) 17.00
Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science (2005) 16.84
qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol (2007) 16.15
Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell (2005) 15.26
Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev (2006) 15.20
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology (2007) 13.20
Principles of cancer therapy: oncogene and non-oncogene addiction. Cell (2009) 10.96
microRNAs as oncogenes and tumor suppressors. Dev Biol (2006) 10.68
MicroRNA signatures in human ovarian cancer. Cancer Res (2007) 9.45
Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet (2002) 7.67
RNA integrity and the effect on the real-time qRT-PCR performance. Mol Aspects Med (2006) 7.37
Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene (2006) 6.61
miRGen: a database for the study of animal microRNA genomic organization and function. Nucleic Acids Res (2006) 4.91
Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci U S A (2006) 4.90
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
RNAi: the nuts and bolts of the RISC machine. Cell (2005) 4.55
Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology (2008) 4.50
Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res (2008) 3.67
MicroRNA expression profiling of single whole embryonic stem cells. Nucleic Acids Res (2006) 3.36
MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology (2008) 3.00
Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem (2008) 2.72
Cancer genomics: small RNAs with big impacts. Nature (2005) 2.55
Altered MicroRNA expression in cervical carcinomas. Clin Cancer Res (2008) 2.42
Discoidin domain receptors: structural relations and functional implications. FASEB J (1999) 2.23
MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harb Symp Quant Biol (2006) 2.12
Discoidin domain receptor 1 tyrosine kinase has an essential role in mammary gland development. Mol Cell Biol (2001) 2.01
Distinct structural characteristics of discoidin I subfamily receptor tyrosine kinases and complementary expression in human cancer. Oncogene (1995) 1.81
The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster. J Exp Clin Cancer Res (2009) 1.66
Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br J Cancer (2007) 1.53
Validation of putative reference genes for gene expression studies in human hepatocellular carcinoma using real-time quantitative RT-PCR. BMC Cancer (2008) 1.44
p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop. EMBO J (2003) 1.44
Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Res (2008) 1.36
A receptor tyrosine kinase found in breast carcinoma cells has an extracellular discoidin I-like domain. Proc Natl Acad Sci U S A (1993) 1.36
Evolution of microRNA expression during human bronchial squamous carcinogenesis. Eur Respir J (2008) 1.35
MicroRNAs--micro in size but macro in function. FEBS J (2008) 1.30
Overexpression of discoidin domain receptor 1 increases the migration and invasion of hepatocellular carcinoma cells in association with matrix metalloproteinase. Oncol Rep (2007) 1.05
Isolation and characterization of an epithelial-specific receptor tyrosine kinase from an ovarian cancer cell line. Cell Growth Differ (1994) 1.00
Future of molecular profiling of human hepatocellular carcinoma. Future Oncol (2007) 0.89
Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med (2007) 6.47
Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med (2009) 5.26
Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ (2009) 3.91
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol (2012) 3.88
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 3.33
A new pumpless extracorporeal interventional lung assist in critical hypoxemia/hypercapnia. Crit Care Med (2006) 3.24
Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology (2002) 3.16
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04
Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int (2010) 2.96
"Hepar divisum"--as a rare donor complication after intraoperative mortality of the recipient of an intended living donor liver transplantation. Liver Transpl (2006) 2.81
Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. J Hepatol (2010) 2.71
Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res (2006) 2.70
Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology (2010) 2.60
Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology (2012) 2.46
Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. Gastroenterology (2004) 2.33
Clinical profiles and outcomes of acute type B aortic dissection in the current era: lessons from the International Registry of Aortic Dissection (IRAD). Circulation (2003) 2.32
Machine perfusion versus cold storage for preservation of kidneys from expanded criteria donors after brain death. Transpl Int (2011) 2.25
Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol (2012) 2.15
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol (2011) 2.13
Biliary complications after liver transplantation: addition of T1-weighted images to MR cholangiopancreatography facilitates detection of cast in biliary cast syndrome. Radiology (2012) 2.01
One or 4 h of "in-house" reconditioning by machine perfusion after cold storage improve reperfusion parameters in porcine kidneys. Transpl Int (2014) 2.00
Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany--limitations of the 'sickest first'-concept. Transpl Int (2010) 1.99
Obesity affects the liver - the link between adipocytes and hepatocytes. Digestion (2010) 1.96
Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med (2013) 1.95
Aortoesophageal fistula after thoracic aortic stent-graft placement: a rare but catastrophic complication of a novel emerging technique. JACC Cardiovasc Interv (2009) 1.94
Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer (2011) 1.89
The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol (2011) 1.87
The White test: a new dye test for intraoperative detection of bile leakage during major liver resection. Arch Surg (2008) 1.86
Aortoesophageal fistula secondary to stent-graft repair of the thoracic aorta. J Endovasc Ther (2004) 1.85
Commensal-associated molecular patterns induce selective toll-like receptor-trafficking from apical membrane to cytoplasmic compartments in polarized intestinal epithelium. Am J Pathol (2002) 1.80
Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology (2013) 1.78
The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response. Gut (2010) 1.77
Human cytomegalovirus infection alters the expression of cellular microRNA species that affect its replication. J Virol (2008) 1.75
Percutaneous endovascular repair of aneurysm after previous coarctation surgery. Circulation (2003) 1.72
Effectiveness of a new carrier-bound fibrin sealant versus argon beamer as haemostatic agent during liver resection: a randomised prospective trial. Langenbecks Arch Surg (2005) 1.69
Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection. Clin Infect Dis (2007) 1.69
Living-related liver transplantation from the view of the donor: a 1-year follow-up survey. Transplantation (2002) 1.66
Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database. J Hepatol (2012) 1.66
Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. J Hepatol (2012) 1.62
EPIBLASTER-fast exhaustive two-locus epistasis detection strategy using graphical processing units. Eur J Hum Genet (2010) 1.62
Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology (2007) 1.59
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology (2009) 1.59
Endoscopic therapy of posttransplant biliary stenoses after right-sided adult living donor liver transplantation. Clin Gastroenterol Hepatol (2005) 1.58
Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting. J Gastrointestin Liver Dis (2007) 1.56
Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection. Pediatr Transplant (2008) 1.56
Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol (2012) 1.56
Evaluation of living liver donors with an all-inclusive 3D multi-detector row CT protocol. Radiology (2006) 1.55
Controlled Oxygenated Rewarming of Cold Stored Livers Prior to Transplantation: First Clinical Application of a New Concept. Transplantation (2016) 1.54
Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J Hepatol (2006) 1.54
Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation. Transplantation (2007) 1.51
Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res (2004) 1.50
MR colonography vs. optical colonoscopy: comparison of patients' acceptance in a screening population. Eur Radiol (2007) 1.48
Mental and physical quality of life in actual living liver donors versus potential living liver donors: a prospective, controlled, multicenter study. Liver Transpl (2009) 1.47
Magnetic endoscopic imaging saves abdominal compression and patient pain in routine colonoscopies. J Dig Dis (2011) 1.47
Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency. Gastroenterology (2009) 1.46
Multicentric evaluation of a clinical and prognostic scoring system predictive of survival after resection of intrahepatic cholangiocarcinomas. Liver Int (2010) 1.46
Validation of putative reference genes for gene expression studies in human hepatocellular carcinoma using real-time quantitative RT-PCR. BMC Cancer (2008) 1.44
Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant. Transplantation (2015) 1.44
Acute hepatic failure in swine: hepatectomy versus vascular occlusion. J Invest Surg (2004) 1.42
Lipid peroxidation products in machine perfusion of older donor kidneys. J Surg Res (2012) 1.42
Does PEEP impair the hepatic outflow in patients following liver transplantation? Intensive Care Med (2006) 1.41
Dynamics of the Romanian waiting list for liver transplantation after changing organ allocation policy. J Gastrointestin Liver Dis (2013) 1.39
Elevated gamma-glutamyltransferase is associated with mortality in lung transplantation for cystic fibrosis. Transpl Int (2011) 1.39
Antiviral treatment of chronic hepatitis B with lamivudine in pediatric renal transplantation. Pediatr Transplant (2006) 1.39
Outcome after kidney transplantation in children with thrombotic risk factors. Pediatr Transplant (2006) 1.39
Serum versus intrahepatic HCV RNA and liver histology. Hepatology (2002) 1.39
De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol (2011) 1.35
Minimally invasive versus open esophagectomy: meta-analysis of outcomes. Dig Dis Sci (2010) 1.35
Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. Cancer Res (2007) 1.34
Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg (2005) 1.32
Right living donor liver transplantation: an option for adult patients: single institution experience with 74 patients. Ann Surg (2003) 1.31
Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatology (2011) 1.30
Quantitative liver function tests in donors and recipients of living donor liver transplantation. Liver Transpl (2006) 1.30
Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer Res (2004) 1.27
Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med (2012) 1.26
Intentional occlusion of the left subclavian artery during stent-graft implantation in the thoracic aorta: risk and relevance. J Endovasc Ther (2004) 1.26